FDA approves Icotyde for moderate-to-severe plaque psoriasis

The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric ...

Research unveils rising homelessness-death connection

A new report, to be presented to policymakers today, uncovers a huge rise in official reports concerning deaths among homeless or precariously housed people in recent years. The investigations, known as Prevention of Future ...

Common blood pressure drug can boost cancer treatment

In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing ...

page 1 from 40